Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with gastrointestinal stromal tumor (GIST).
Patients who have had disease progression during imatinib therapy with 800 mg.
Ability to understand and willingness to sign a written informed consent document.
You may not be if
Patients with prior or concomitant malignancies other than GIST with the exception of previous or concomitant basal cell skin cancer or previous cervical carcinoma in situ.
A history of impaired cardiac function or uncontrolled cardiovascular disease.
Severe and/or uncontrolled concurrent disease that could cause unacceptable safety risks such as impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of AMN107.
Currently taking certain medications that could affect an electrocardiogram result.
Women who are pregnant or breast feeding.
Patients unwilling or unable to comply with the protocol.
Clareo Health | Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)
